The cost-effectiveness of toripalimab combined with chemotherapy versus chemotherapy alone in the first-line treatment of extensive-stage small cell lung cancer in China: the perspective of the medical and health system based on the EXTENTORCH study

At the current willingness-to-pay threshold for Chinese patients, the combination of toripalimab and chemotherapy demonstrates superior cost-effectiveness compared to traditional chemotherapy.

Authors

Jianguo Zhao (ORCID: https://orcid.org/0000-0001-6587-4823)
Zekai Zhao (ORCID: https://orcid.org/0000-0002-3816-5471)
Shengkai Zhao
Xueying Jin (ORCID: https://orcid.org/0009-0007-4152-5769)

Institutions

Shanxi Medical University (CN)
Guilin University of Aerospace Technology (CN)
Guilin University of Technology (CN)
First Hospital of Shanxi Medical University (CN)
Shaoxing People's Hospital (CN)
Guilin University
Jining Medical University (CN)
Guilin University of Electronic Technology (CN)

Publication Details

Journal: Expert Review of Anticancer Therapy
Published: 2025-08-18
DOI: https://doi.org/10.1080/14737140.2025.2549007
Primary Topic: Lung Cancer Research Studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

The cost-effectiveness of toripalimab combined with chemotherapy versus chemotherapy alone in the first-line treatment of extensive-stage small cell lung cancer in China: the perspective of the medical and health system based on the EXTENTORCH study

Jianguo Zhao, Zekai Zhao, Shengkai Zhao, Xueying Jin

Aug 18, 2025

Expert Review of Anticancer Therapy

Lung Cancer Research Studies

article

The cost-effectiveness of toripalimab combined with chemotherapy versus chemotherapy alone in the first-line treatment of extensive-stage small cell lung cancer in China: the perspective of the medical and health system based on the EXTENTORCH study

Jianguo Zhao, Zekai Zhao, Shengkai Zhao, Xueying Jin

August 18, 2025article en

Abstract

At the current willingness-to-pay threshold for Chinese patients, the combination of toripalimab and chemotherapy demonstrates superior cost-effectiveness compared to traditional chemotherapy.

Expert Review of Anticancer TherapyVol. 25(12)

Shanxi Medical University (CN), Guilin University of Aerospace Technology (CN), Guilin University of Technology (CN), First Hospital of Shanxi Medical University (CN), Shaoxing People's Hospital (CN), Guilin University, Jining Medical University (CN), Guilin University of Electronic Technology (CN)

Good health and well-being

Openalex Percentile: Top 70%

Lung Cancer Research Studies

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The cost-effectiveness of toripalimab combined with chemotherapy versus chemotherapy alone in the first-line treatment of extensive-stage small cell lung cancer in China: the perspective of the medical and health system based on the EXTENTORCH study — Jianguo Zhao, Zekai Zhao, et al. · Expert Review of Anticancer Therapy (2025) | TGRS Research Map | TGRS